The Extracellular Signal-regulated Kinase (ERK) Pathway: a Potential Therapeutic Target in Hypertension

Overview

Journal J Exp Pharmacol

Publisher Dove Medical Press

Date 2016 May 18

PMID 27186119

Citations 18

Authors

Richard E Roberts

Affiliations

Soon will be listed here.

Abstract

Hypertension is a risk factor for myocardial infarction, stroke, renal failure, heart failure, and peripheral vascular disease. One feature of hypertension is a hyperresponsiveness to contractile agents, and inhibition of vasoconstriction forms the basis of some of the treatments for hypertension. Hypertension is also associated with an increase in the growth and proliferation of vascular smooth muscle cells, which can lead to a thickening of the smooth muscle layer of the blood vessels and a reduction in lumen diameter. Targeting both the enhanced contractile responses, and the increased vascular smooth muscle cell growth could potentially be important pharmacological treatment of hypertension. Extracellular signal-regulated kinase (ERK) is a member of the mitogen-activated protein kinase family that is involved in both vasoconstriction and vascular smooth muscle cell growth and this, therefore, makes it attractive therapeutic target for treatment of hypertension. ERK activity is raised in vascular smooth muscle cells from animal models of hypertension, and inhibition of ERK activation reduces both vascular smooth muscle cell growth and vasoconstriction. This review discusses the potential for targeting ERK activity in the treatment of hypertension.

Citing Articles

Molecular Spies in Action: Genetically Encoded Fluorescent Biosensors Light up Cellular Signals.

Gest A, Sahan A, Zhong Y, Lin W, Mehta S, Zhang J Chem Rev. 2024; 124(22):12573-12660.

PMID: 39535501 PMC: 11613326. DOI: 10.1021/acs.chemrev.4c00293.

Engineering growth factor ligands and receptors for therapeutic innovation.

An X, Paoloni J, Oh Y, Spangler J Trends Cancer. 2024; 10(12):1131-1146.

PMID: 39389907 PMC: 11631651. DOI: 10.1016/j.trecan.2024.09.006.

An in silico molecular docking and simulation study to identify potential anticancer phytochemicals targeting the RAS signaling pathway.

Azmal M, Paul J, Prima F, Talukder O, Ghosh A PLoS One. 2024; 19(9):e0310637.

PMID: 39298437 PMC: 11412525. DOI: 10.1371/journal.pone.0310637.

Interdependency and differential expression of ERK1 and ERK2 in breast and melanoma cell lines.

Moulik S, Karmakar S, Basu A, Ali M, Chatterjee A J Egypt Natl Canc Inst. 2024; 36(1):27.

PMID: 39278984 DOI: 10.1186/s43046-024-00233-3.

Therapeutic Potential of Chlorogenic Acid in Chemoresistance and Chemoprotection in Cancer Treatment.

Cortez N, Villegas C, Burgos V, Ortiz L, Cabrera-Pardo J, Paz C Int J Mol Sci. 2024; 25(10).

PMID: 38791228 PMC: 11121551. DOI: 10.3390/ijms25105189.

References

Cruzado M, Risler N, Miatello R, Yao G, Schiffrin E, Touyz R . Vascular smooth muscle cell NAD(P)H oxidase activity during the development of hypertension: Effect of angiotensin II and role of insulinlike growth factor-1 receptor transactivation. Am J Hypertens. 2005; 18(1):81-7. DOI: 10.1016/j.amjhyper.2004.09.001. View

Lee S, Wang W, Finlay G, Fanburg B . Serotonin stimulates mitogen-activated protein kinase activity through the formation of superoxide anion. Am J Physiol. 1999; 277(2):L282-91. DOI: 10.1152/ajplung.1999.277.2.L282. View

Kida T, Chuma H, Murata T, Yamawaki H, Matsumoto S, Hori M . Chronic treatment with PDGF-BB and endothelin-1 synergistically induces vascular hyperplasia and loss of contractility in organ-cultured rat tail artery. Atherosclerosis. 2010; 214(2):288-94. DOI: 10.1016/j.atherosclerosis.2010.11.001. View

Eguchi S, Dempsey P, Frank G, Motley E, Inagami T . Activation of MAPKs by angiotensin II in vascular smooth muscle cells. Metalloprotease-dependent EGF receptor activation is required for activation of ERK and p38 MAPK but not for JNK. J Biol Chem. 2000; 276(11):7957-62. DOI: 10.1074/jbc.M008570200. View

Childs T, WATSON M, Sanghera J, Campbell D, Pelech S, Mak A . Phosphorylation of smooth muscle caldesmon by mitogen-activated protein (MAP) kinase and expression of MAP kinase in differentiated smooth muscle cells. J Biol Chem. 1992; 267(32):22853-9. View

Xiao D, Pearce W, Longo L, Zhang L . ERK-mediated uterine artery contraction: role of thick and thin filament regulatory pathways. Am J Physiol Heart Circ Physiol. 2004; 286(5):H1615-22. DOI: 10.1152/ajpheart.00981.2003. View

Hawes B, Luttrell L, van Biesen T, Lefkowitz R . Phosphatidylinositol 3-kinase is an early intermediate in the G beta gamma-mediated mitogen-activated protein kinase signaling pathway. J Biol Chem. 1996; 271(21):12133-6. DOI: 10.1074/jbc.271.21.12133. View

Kim J, Lee Y, Lee C, Choi W, Lee C, Kim J . Mitogen-activated protein kinase contributes to elevated basal tone in aortic smooth muscle from hypertensive rats. Eur J Pharmacol. 2005; 514(2-3):209-15. DOI: 10.1016/j.ejphar.2005.03.030. View

Mulvany M, Hansen O, Aalkjaer C . Direct evidence that the greater contractility of resistance vessels in spontaneously hypertensive rats is associated with a narrowed lumen, a thickened media, and an increased number of smooth muscle cell layers. Circ Res. 1978; 43(6):854-64. DOI: 10.1161/01.res.43.6.854. View

10.

Banes A, Florian J, Watts S . Mechanisms of 5-hydroxytryptamine(2A) receptor activation of the mitogen-activated protein kinase pathway in vascular smooth muscle. J Pharmacol Exp Ther. 1999; 291(3):1179-87. View

11.

Lane K, Beese L . Thematic review series: lipid posttranslational modifications. Structural biology of protein farnesyltransferase and geranylgeranyltransferase type I. J Lipid Res. 2006; 47(4):681-99. DOI: 10.1194/jlr.R600002-JLR200. View

12.

Jing L, Zhang J, Sun J, Guo F, An X, Yang K . Inhibition of extracellular signal-regulated kinases ameliorates hypertension-induced renal vascular remodeling in rat models. Int J Mol Sci. 2012; 12(12):8333-46. PMC: 3257072. DOI: 10.3390/ijms12128333. View

13.

Ngai P, Walsh M . Inhibition of smooth muscle actin-activated myosin Mg2+-ATPase activity by caldesmon. J Biol Chem. 1984; 259(22):13656-9. View

14.

Muthalif M, Karzoun N, Gaber L, Khandekar Z, Benter I, Saeed A . Angiotensin II-induced hypertension: contribution of Ras GTPase/Mitogen-activated protein kinase and cytochrome P450 metabolites. Hypertension. 2000; 36(4):604-9. DOI: 10.1161/01.hyp.36.4.604. View

15.

Bruner C . Vascular responsiveness in rats resistant to aldosterone-salt hypertension. Hypertension. 1992; 20(1):59-66. DOI: 10.1161/01.hyp.20.1.59. View

16.

Yokouchi K, Numaguchi Y, Kubota R, Ishii M, Imai H, Murakami R . l-Caldesmon regulates proliferation and migration of vascular smooth muscle cells and inhibits neointimal formation after angioplasty. Arterioscler Thromb Vasc Biol. 2006; 26(10):2231-7. DOI: 10.1161/01.ATV.0000239441.29687.97. View

17.

Eguchi S, Numaguchi K, Iwasaki H, Matsumoto T, Yamakawa T, Utsunomiya H . Calcium-dependent epidermal growth factor receptor transactivation mediates the angiotensin II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. J Biol Chem. 1998; 273(15):8890-6. DOI: 10.1074/jbc.273.15.8890. View

18.

Tristano A, Castejon A, Castro A, Cubeddu L . Effects of statin treatment and withdrawal on angiotensin II-induced phosphorylation of p38 MAPK and ERK1/2 in cultured vascular smooth muscle cells. Biochem Biophys Res Commun. 2006; 353(1):11-7. DOI: 10.1016/j.bbrc.2006.11.044. View

19.

Rizzoni D, Porteri E, Guefi D, Piccoli A, Castellano M, Pasini G . Cellular hypertrophy in subcutaneous small arteries of patients with renovascular hypertension. Hypertension. 2000; 35(4):931-5. DOI: 10.1161/01.hyp.35.4.931. View

20.

Roberts R . Role of the extracellular signal-regulated kinase (Erk) signal transduction cascade in alpha(2) adrenoceptor-mediated vasoconstriction in porcine palmar lateral vein. Br J Pharmacol. 2001; 133(6):859-66. PMC: 1572855. DOI: 10.1038/sj.bjp.0704149. View